Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
NCT04143724
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
99
Enrollment
INDUSTRY
Sponsor class
Conditions
Beta-Thalassemia
Interventions
DRUG:
ACE-536
Sponsor
Celgene
Collaborators
[object Object]